OBJECTIVES: Preoperative liver dysfunction is a well-known risk factor for adverse events after major surgery. However, there is only little data regarding the precise role of the Model of End-Stage Liver Disease (MELD) score and the De Ritis ratio (DRR, alanine transaminase/aspartate aminotransferase) as a predictor for outcome after left ventricular assist device (LVAD) implantation.
INTRODUCTION
The number of patients with advanced heart failure (HF) unresponsive to conventional medical therapy and ineligible for heart transplant is increasing rapidly. Since the publication of the Randomized Evaluation of Mechanical Assistance in the Treatment of Congestive Heart Failure (REMATCH) trial in 2001, left ventricular assist devices (LVADs) have become an established life-saving therapeutic option in the treatment of elderly patients with end-stage HF [1] . Because of technical improvements and progress in surgical and anaesthesiological management with improved survival, this technique has been used more liberally even in patients with pre-existing organ failure, e.g. acute liver dysfunction [2] .
In contrast to the field of heart transplantation, there is only little guidance on the selection of patients for mechanical support and handling of patients with pre-existing organ damage, e.g. liver dysfunction [3] . Over time, a large number of variables have been identified, largely by univariable analysis, to be associated with increased mortality in patients with HF undergoing LVAD implantation [4, 5] .
However, the preoperative hepatic function seems to play a crucial role in determining adverse events after LVAD implantation †The first two authors contributed equally to this work.
including right HF, acute kidney injury and bleeding events [6] . Therefore, a comprehensive evaluation of hepatic function and proper patient selection prior to LVAD placement is mandatory.
The Model for End-Stage Liver Disease (MELD) is a scoring system for the assessment of liver function that incorporates 3 simple laboratory parameters [serum creatinine, bilirubin and international normalized ratio (INR) for prothrombin time] and was initially developed as a model for predicting survival in patients after trans-jugular intrahepatic portosystemic shunt [7] . The MELD has been shown to be a useful diagnostic tool for prediction of mortality in patients undergoing cardiac surgery, major abdominal surgery, cardiac transplantation as well as in ambulatory patients with HF [8] [9] [10] . Recently published studies could demonstrate that preoperative MELD is predictive of mortality, respiratory and renal dysfunction as well as perioperative transfusion requirements after LVAD implantation [11] [12] [13] . However, all cited studies included left as well as biventricular devices, pulsatile as well as continuous-flow devices and intracorporeal as well as paracorporeal devices. Therefore, these results cannot be applied to patients currently treated with continuous-flow devices of the latest generation. In addition, the MELD score has been criticized for several reasons including the limitations of serum creatinine as marker of renal function and the inability of the INR to reflect the severity of liver disease in patients with oral anticoagulation [14] . The alanine transaminase:aspartate aminotransferase ratio [ALT/AST; De Ritis ratio (DRR)] provides useful diagnostic and prognostic information in patients with liver disease of different aetiologies but has not been evaluated in LVAD candidates [15] . Therefore, the aim of the present study was to investigate the role of the MELD score and the DRR for the risk stratification after implantation of the HeartWare LVAD (HVAD).
METHODS

Study design
This retrospective database analysis included 63 consecutive patients with refractory, end-stage HF and LVAD implantation as a bridge to transplantation or destination therapy between January 2012 and August 2014. We decided to choose this time frame as a separate section for thoracic transplant, and mechanical heart/ lung support was established within the Department of Cardiothoracic Surgery in January 2012 and we aimed to grant a follow-up of at least 180 days for every patient.
The indication for LVAD implantation was discussed in an interdisciplinary consensus conference of cardiologists and cardiac surgeons ('Heart Team') for each patient.
Clinical charts were reviewed and perioperative haemodynamic, laboratory and historical data were retrieved for all 63 patients. There was 100% data retrieval for each criterion. We used the Standards for Reporting of Diagnostic Accuracy statement for conducting the study and preparing the manuscript [16] .
End-points
The primary end-point was overall survival at 180 days after LVAD implantation (survival on LVAD support, after heart transplant or after explantation for myocardial recovery). Secondary end-points included overall survival at 30 days after LVAD implantation (survival on LVAD support, after heart transplant or after explantation for myocardial recovery), postoperative acute kidney injury with need for renal replacement therapy (RRT), reexploration for bleeding, prolonged ventilation time >72 h and gastrointestinal bleeding. All patients completed a follow-up period of at least 180 days and were divided into 2 groups depending on the 30-and 180-day survival, respectively. The demographic and perioperative variables of the 30-and 180-day survivors and non-survivors were compared to identify the predictors of the 30-day and 180-day overall mortality.
Ethics principles
The present study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Institutional Ethic Review Board of the University Hospital Essen. Written informed consent from the patient or the patient's next of kin was obtained.
Surgical procedure and postoperative care
Technical details of the LVAD implantation have been previously described in detail [17] . Briefly, device implantation was performed through a standard sternotomy using normothermic cardiopulmonary bypass with beating heart. The sewing ring was attached epicardially to the left ventricular apex, and the inflow cannula was inserted through the sewing ring into the left ventricle. The outflow graft was cut to length and sewn to the ascending aorta using an end-to-side anastomosis. The percutaneous lead was tunnelled to exit in the right upper quadrant. After de-airing was completed, the clamp on the outflow graft was removed, and HVAD pump speed was adjusted to accomplish full flow. Pharmacological support and fluid administration were adjusted to provide appropriate right heart function for successful weaning from cardiopulmonary bypass. Our anticoagulation regimen included intravenous unfractionated heparin once chest tube drainage was less than 50 ml/h to maintain an activated partial thromboplastin time of 50-60 s. Acetylsalicylic acid (100-300 mg/ day) was started 48-72 h after HVAD pump implant. Warfarin replaced heparin once the patient was stable, chest tubes had been removed and gastrointestinal function had returned. Warfarin was adjusted to achieve an INR of 2.5-3.0.
Assessment of liver function
Assessment of liver function was based on total bilirubin, AST, ALT, gamma-glutamyl transpeptidase as well as MELD score and DRR.
We used the United Network for Organ Sharing modification of the MELD score [18] .
MELD=3:78 Â lnðBiliÞ þ 11:2 Â lnðINRÞ þ 9:57 Â lnðCrÞ þ 6:43:
Any variable with a value <1 is assigned a value of 1 to avoid negative scores. Thus, the minimum possible MELD score is 6.43.
De Ritis describes the ratio between the serum levels of AST and ALT. Variables with P < 0.1 in the univariable analysis were included in a logistic regression model with backward selection to determine independent factors associated with 30-day and 180-day mortality. Model calibration was tested using the Hosmer-Lemeshow test. The Kaplan-Meier survival method was used to assess post-LVAD survival. Log-rank tests were used to assess statistical significance in survival differences between the groups. Statistical significance was assumed for a P-value <0.05.
Sample size calculation
On the basis of recently published data on adults undergoing LVAD implantation, we aimed to detect a difference in MELD score between survivors and non-survivors of 4 with an SD of 7 units. The known and previously reported mortality after 180 days after LVAD implantation ranges between 25% and 30%. With a given probability of Type I error (a) of 0.05, and a power (1 -b) of 0.8, the sample size calculation revealed required a minimum size of 50 patients in total.
RESULTS
Descriptive data analysis
During the observation period, 63 patients with a mean age of 59.9 ± 8.3 years [range 39-83 years, 52 male (82.6%)] underwent HVAD implantation at our institution. The initial LVAD goal was bridge to transplant in 12 (19.0%) and destination therapy in 51 (80.6%) patients. The majority of patients suffered from ischaemic (n = 35) or dilatative cardiomyopathy (n = 24). In addition, primary cardiac disease was classified as myocarditis in 2 patients. Mean preoperative ejection fraction was 16.3 ± 7.7%, 13 patients required preoperative RRT and 9 patients were on extracorporeal life support. Mean Interagency Registry for Mechanically Assisted Circulatory Support level was 2.8 ± 1.3, mean preoperative MELD was 12.7 ± 7.2 and mean preoperative DRR was 2.01 ± 4.4.
Survivors versus non-survivors
After 30 days, 53 (84%) patients were alive. Baseline demographics including age, gender, prevalence of significant comorbidities and Interagency Registry for Mechanically Assisted Circulatory Support level did not differ between the 2 groups (see Table 1 ). Preoperative extracorporeal life support was necessary in 40% of non-survivors compared with 9.4% of survivors after 30 days (P = 0.029). In addition, preoperative DRR (6.6 ± 10.1 vs 1.1 ± 1.0, P = 0.001), total bilirubin (2.9 ± 2.9 mg/dl vs 1.1 ± 0.8 mg/dl, P = 0.026) as well as gamma-glutamyl transpeptidase levels (81.1 ± 23.5 vs 127.5 ± 93.6 U/l, P = 0.003) were significantly higher in non-survivors than in survivors after 30 days. Levels of other liver enzymes, serum creatinine, C-reactive protein, brain natriuretic peptide as well as MELD score and DRR were comparable between survivors and non-survivors.
After 180 days, 45 patients (71%) were alive. Non-survivors were characterized by a more complicated postoperative course indicated by a higher incidence of acute kidney injury with need for RRT [7 ( 38.9%) vs 6 (13.3%), P = 0.038] and longer ventilation time (647.3 ± 566.9 vs 184.6 ± 265.5, P = 0.003). Consecutively, intensive care unit stay was significantly longer (19.8 ± 21.1 vs 18.0 ± 64.8 days, P = 0.022). In addition, AST (102 ± 220.8 vs 57.8 ± 123.4, P = 0.041), MELD score (16.1 ± 8.8 vs 11.4 ± 6.1, P = 0.017) and DRR (4.2 ± 7.8 vs 1.1 ± 1.1, P = 0.001) were significantly higher in nonsurvivors. Other demographics and prevalence of relevant comorbidities were comparable between both groups.
Predictors of mortality
In univariable analyses, a DRR >1.37 [odds ratio (OR) 17.2, 95% confidence interval (CI) 3.20-93.70, P = 0.001], a MELD >14.9 (OR 4.9, 95% CI 1.14-21.50, P = 0.033) and the preoperative use of extracorporeal life support (OR 6.4, 95% CI 1.34-30.61, P = 0.020) were predictors of mortality within 30 days. Interagency Registry for Mechanically Assisted Circulatory Support Levels 1 or 2 (OR 4.4, 95% CI 1.38-14.21, P = 0.012), the preoperative need for RRT (OR 4. 1, 95% CI 1.15-14.87, P = 0.030) and a DRR >1.37 (OR 8.5, 95% CI 2.46-29.60, P = 0.001) were predictive of 180-day mortality in univariable analyses (Table 2) . After adjusting for all significant factors in univariable analyses, only DRR remained an independent predictor of 30-and 180-day mortality (30-day mortality: OR 4.5, 95% CI 0.87-22.9, P = 0.042 and 180-day mortality: OR 4.1, 95% CI 1.2-14.8, P = 0.03). In addition, an elevated DRR was associated with postoperative acute kidney injury with need for RRT (OR 4.21, 95% CI 0.882-20.490, P = 0.02) and prolonged postoperative ventilation time >72 h (OR 3.851, 95% CI 0.911-21.536, P = 0.049). In contrast, no correlation could be observed between the DRR and the incidence of rethoracotomy, the development of gastrointestinal bleeding or the amount of blood products given in the perioperative course.
Receiver operator characteristics analyses
The preoperative MELD score showed a moderate predictive value for mortality after 180 days (area under the curve 0.691, standard error 0.107, 95% CI 0.057-0.481, P = 0.900) (Fig. 1) . A cut-off value of 14.7 for the MELD score revealed a sensitivity and specificity of 70.0% and 66.0%, respectively. In contrast, the diagnostic accuracy for the DRR was more reliable with an area under the curve 0.834 (95% CI 0.678-0.989, standard error 0.079, P = 0.007), a sensitivity of 80% and a specificity of 81.0% when using a cut-off value of 1.37. Liver enzymes, serum creatinine and INR showed low predictive values for mortality after 30 and 180 days.
Subgroup analyses according to Model of EndStage Liver Disease/De Ritis ratio
On the basis of the best cut-off value for discriminating between survivors and non-survivors from receiver operator characteristics analyses, patients were dichotomized into those with MELD values > _14.7 and those with values <14.7 and a DRR > _1.37 and those with a DRR <1.37, respectively (Table 3) . Dividing patients in subgroups based on their DRR, age (63.5 ± 9.5 vs 58.5 ± 7.5 years, P = 0.03), AST (73.6 ± 129.1 I/U vs 62.4 ± 135.4 I/U, P = 0.01) and total bilirubin (1.2 ± 1.5 mg/dl vs 1.8 ± 1.4 mg/dl, P = 0.01) were significantly higher in patients with elevated DRR, whereas INR (1.3 ± 0.4 vs 1.7 ± 1.1, P = 0.02) and C-reactive protein (3.1 ± 3.9 vs 5.7 ± 5.3, P = 0.01) were lower in this group.
Most preoperative characteristics were similar between groups stratified by MELD score. As expected, preoperative MELD components creatinine (2.1 ± 1.2 vs 1.3 ± 0.3 mg/dl, P < 0.001) and bilirubin levels (2.3 ± 2.1 mg/dl vs 0.8 ± 0.4 mg/dl, P < 0.001) were significantly higher for patients with an elevated MELD score, whereas INR was lower (1.1 ± 0.1 vs 1.8 ± 1.0 P < 0.001). In addition, C-reactive protein values were higher (5.6 ± 5.8 mg/dl vs 2.8 ± 2.9 mg/dl, P = 0.04) in patients with a MELD score > _14.7 and brain natriuretic peptide levels tended to be higher in this group (1618.8 ± 1507.6 ng/dl vs 992.1 ± 893.8 ng/dl, P = 0.08).
Patients with a MELD score > _14.9 showed a significantly impaired outcome after 30 days compared with patients with scores <14.9 [30 days survival 70.8% (95% CI 21.3-28.5) vs 92.3% (95% CI 26.4-30.2, P = 0.030]. In addition, 30-day survival was lower in patients with a DRR <1.37 compared to those with values >1.37 [55.6% (95% CI 16.7-26.3) vs 95.6% (95% CI 27.9-30.5), P < 0.001] (Fig. 2) .
A superior survival after 180 days could be observed in patients with a lower DRR [84.5% (95% CI 148.3-174.6) vs 38.9% (95% CI 46.0-119.0), P < 0.001] but only a trend towards better survival could be observed with lower MELD scores [79.5% (95% CI 133.1-169.7) vs 58.3% (87.8-148.5), P = 0.069].
In addition, we performed a Cox proportional hazard ratio analysis based on MELD and DRR scores. 
DISCUSSION
In a retrospective, single-centre database analysis of patients with end-stage HF undergoing LVAD implantation, we demonstrated that the DRR is predictive for early and mid-term mortality as well as for comorbidities such as acute renal failure, ventilation time and intensive care unit stay. In addition, we found a better predictive value for the DRR compared with the MELD score.
With the advent of durable and reliable mechanical circulatory support, LVAD implantation as bridge-to-transplant therapy has become the standard of care for many patients awaiting transplant or as destination therapy in patients not eligible for transplant [1] .
Although it is well established that patient selection is the primary determinant of success with LVAD therapy, there is only little guidance in the handling of patients with pre-existing organ damage, e.g. liver dysfunction [3] .
Over time, a large number of variables have been identified to be associated with increased mortality in patients with HF undergoing LVAD implantation [4, 5] . Many patients with advanced HF suffer from mild-to-moderate abnormalities of renal or hepatic function with pathological liver function tests. This hepatic dysfunction can be considered to be the result of impaired perfusion, elevated right-sided cardiac pressures or secondary to drug toxicity. The relationship between cardiac and hepatic dysfunction has been a well-recognized entity for over 2 centuries. According to the 'Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) trial', analysing liver function tests of 2679 patients with symptomatic chronic HF, abnormal levels of total bilirubin, direct bilirubin, alkaline phosphatase and albumin are predictors of outcome with total bilirubin being more predictive of adverse prognosis than the New York Heart Association functional class, left ventricular ejection fraction, diabetes mellitus and serum creatinine [19] .
Accordingly, there is a growing body of evidence in the literature that the preoperative liver function has a significant impact on outcome after LVAD implantation. However, several centres do not generally exclude patients with chronic liver dysfunction or pre-existing acute hepatic failure from LVAD implantation demonstrating excellent rates of recovery and survival in a high proportion of these patients [2] . Against this background, individual risk stratification of patients with impaired liver function undergoing LVAD implantation seems to be reasonable. Different approaches for risk assessment based on the liver function have been investigated.
Yost et al. [20] could show that MELD can be used to reliably predict postoperative right HF and the necessity for RVAD implantation. In a retrospective-single institution study including 211 LVAD implantations between 1996 and 2007, the MELD score was significantly correlated with the use of blood products, prolonged intensive care unit stay and requirement for RRT. In addition, MELD scores predicted decreased survival at 6 months [11] . A recently published study could confirm that the MELD score is correlated with the postoperative administration of red blood cells, platelets, plasma and total blood product units [21] . Others could prove the predictive value of the MELD score for early mortality and major morbidities after LVAD implantation [12, 13] . A mean MELD score of 14.4 ± 5.9 was reported by Bonde et al. [12] . Actuarial incidence of infections, bleeding events and cardiovascular dysfunction at 6 months was 65.4%, 52.1% and 45.6%, respectively. Multivariable Cox proportional hazards model (controlling for gender, type of device, diagnosis, intention to treat, urgency and inotropic use) confirmed that MELD score predicted mortality as well as respiratory and renal dysfunction at 6 months [12] .
In addition, prediction of reversibility of liver or renal function in patients with end-stage HF after LVAD implantation seems to be possible with a scoring system consisting of preoperative bilirubin and creatinine levels adjusted by the patient's age [22] .
Data from the United Network for Organ Sharing registry with a total of 39 711 patients undergoing heart transplantation demonstrated that elevated MELD-XI scores were associated with an increased need for preoperative inotropic support, extracorporeal membrane oxygenation, intra-aortic balloon pumping and mechanical ventilation as well as an increased long-term mortality [13] .
However, a careful look at the parameters of the MELD score reveals its limitations and resultant caution that should be given to its ostensibly objective parameters. INR was designed to standardize the anticoagulation effect of warfarin and may not reflect the severity of liver disease. Accordingly, two studies that used different assays to measure INR led to significantly different MELD scores between transplant centres [23] . Although serum creatinine is currently accepted as 'gold standard' to diagnose kidney failure, it is known to be an inadequate and delayed marker of acute changes in renal function [24] . Against this background, other markers of severity of liver dysfunction might be more suitable for the prediction of outcome after LVAD implantation.
Measurement of ALT and AST enzymatic activity in circulation is still the most commonly used biochemistry test in clinical practice, when the aim is to evaluate putative liver injury. Aminotransferases are enzymes that catalyse the transfer of an alpha-amino group from an amino acid to an alpha-keto acid. ALT is localized solely in the cellular cytoplasm, whereas AST is both cytosolic (20% of total activity) and mitochondrial (80% of total activity). ALT is more specific to the liver, as AST is also found in cardiac and skeletal muscle and red blood cells.
The ratio of the serum activities of AST and ALT was first described by Fernando De Ritis et al. [25] in 1957. The ratio of AST to ALT may be used to distinguish between different causes of liver damage: Most causes of liver cell injury are associated with an AST that is lower than the ALT. However, an AST to ALT ratio of 2:1 or greater is suggestive of alcoholic liver disease. The AST to ALT ratio can also occasionally be elevated in a liver disease pattern in patients with non-alcoholic steatohepatitis, and it is frequently elevated in an alcoholic liver disease pattern in patients with hepatitis C who have developed cirrhosis.
In addition, the DRR is related to the severity of liver disease: The ratio increases in progressive liver functional impairment and is characterized by 81.3% sensitivity and 55.3% specificity in identifying cirrhotic patients who die within 1 year of follow-up [26] .
Most other studies investigating the predictive value of liver enzymes or liver risk scores in LVAD patients are limited by the fact that patients were enrolled for a very long period of 20 years. In addition, the majority of cited studies included left as well as biventricular devices, pulsatile as well as continuous-flow devices and intracorporeal as well as paracorporeal devices. The advancement in treatment of patients with end-stage HF, development of the newer VAD generation makes it hard to translate this data to the current LVAD population. In contrast, the presented study only included patients treated with a single type of a continuous-flow LVAD (HeartWare) in time span of patient inclusion, thus warranting standardized treatment plans and treatment teams including a specialized physician, surgeon and intensive care team for mechanical pulmonary and circulatory assist and thoracic transplantation. 
Limitations
There are several potential limitations to this study, many of which are inherent to the nature of single-centre cohort studies. As this was a non-blinded, retrospective evaluation, patient selection and management biases likely exist that may have influenced study end-points and MELD as well as DRR dichotomization thresholds. This is especially important, when pre-, intra-and postoperative interventions can significantly affect the parameter under evaluation. Despite standardized treatment plans, individual decisions in medication and therapy can influence events. In addition, subjects in this cohort did not have liver biopsies to rule out concomitant cirrhosis as a confounder of results, which is of concern in subjects with a high prevalence of concomitant RV dysfunction and chronic hepatic congestion. No study subject had preoperative ultrasound evidence of cirrhosis.
Finally, because of the small number of patients, the power to detect a difference between the groups is limited.
CONCLUSION
Preoperative DRR predicts early and mid-term mortality as well as relevant morbidities including renal and respiratory impairment more reliable than the MELD score in patients undergoing LVAD implantation. Therefore, the DRR should help to obtain a more precise understanding of the patient's clinical condition prior to LVAD implantation and should be considered within preoperative risk stratification and patient selection for LVAD implantation.
